Moderna To Focus On Messenger RNA Approaches To Recreate Therapeutic Proteins
This article was originally published in The Pink Sheet Daily
Executive Summary
The latest biotech to emerge from Flagship Ventures’ incubator is Moderna, which plans to focus on rare diseases in-house while out-licensing its technology for larger indications.